OpGen Inc. (NASDAQ:OPGN)

OpGen Inc. (NASDAQ:OPGN) Awarded $860,000 CDC Contract

OpGen Inc. (NASDAQ:OPGN)

Shares of OpGen Inc.(NASDAQ:OPGN) fell 1.4% after the Center for Disease Control and Prevention awarded the company a contract for the development of clinical support tools for antimicrobial stewardship and infection control. The agency has since granted the company $860,000 for the development of a cloud-based mobile software which is to be used in low and middle-income countries.

OpGen Inc. (NASDAQ:OPGN)

CDC Contract Award

OpGen Inc. (NASDAQ:OPGN) is to work with Teqqa, LLC and Universidad El Bosque (UEB) of Bogota, Colombia led by Maria Virginia Villegas, M.D., M.Sc. to bring the solution to fruition. Teqqa is to provide a cloud and mobile based software platform to support antimicrobial stewardship.

The platform is to be used to identify patients that require infection control precautions and assist in the implementations of the necessary precautions. The software will be translated into Spanish to support WHONET data integration.

“OpGen looks forward to working with the CDC to help address this urgent global need,” stated Evan Jones, CEO of OpGen. “Improving antimicrobial stewardship worldwide has been identified by the CDC, the World Health Organization (WHO) and governments worldwide as a core activity in the fight to contain and manage infections from multidrug-resistant pathogens.”

OpGen Inc. (NASDAQ:OPGN) is also developing the Acuitas AMR Gene Panel u5.47, a PCR test designed to detect antibiotic resistance genes. The test can detect up to five bacterial pathogens in clinical isolate and urine specimens. It can also be used to detect up to 47 antimicrobial resistance genes.

According to OpGen’s senior vice president of research and development, Dr. Terry Walker, antimicrobial drug resistance is an urgent global health concern.

“Our data show that the Acuitas AMR Gene Panel accurately detects and quantitates key complicated urinary tract infection pathogens. We are encouraged by the development data for Acuitas Lighthouse Knowledgebase prediction algorithms currently in development,” said Dr. Walker.

OPGN Stock Performance

The CDC award did little to strengthen investor confidence in the precision medicine company. The stock has underperformed the overall industry, having shed more than 70% in market value since the start of the year.

OpGen Inc. (NASDAQ:OPGN) is currently trading in a downtrend as investors sentiments on the street continue to drop. However, the stock is currently rated as a ‘strong buy’ by two analyst firms according to data compiled by Zacks Investment Research.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OpGen Inc (NASDAQ:OPGN)

OpGen Inc (NASDAQ:OPGN) Details New Tests For Predicting Antibiotic Susceptibility

OpGen Inc (NASDAQ:OPGN)

OpGen Inc (NASDAQ:OPGN) shares traded higher after the company presented the results of their Acuitas study. The Acuitas® AMR Gene Panel u5.47, and the Acuitas Lighthouse® are being developed for the prediction of antibiotic susceptibility. The stock was up by 1.33% in Friday’s trading session to end the week at $0.304 a share.

OpGen Inc (NASDAQ:OPGN)
One month OPGN stock price chart

Antibiotics Susceptibility Tests

OpGen Inc (NASDAQ:OPGN) presented at the 2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance and included data based on the analysis of the Merck Study for Monitoring Antimicrobial Resistance Trends or SMART. OpGen Inc (NASDAQ:OPGN) is developing Acuitas AMR Gene Panel as a research use only semi-quantitative PCR for the detection of five bacterial pathogens in clinical isolates and urine specimens.

“We are encouraged by the development data for Acuitas Lighthouse Knowledgebase prediction algorithms currently in development. The results from this study suggest the AMR Gene Panel can potentially aid in the rapid detection of resistance genes days ahead of antibiotic susceptibility testing,” said Terry Walker, Ph.D., OpGen Inc (NASDAQ:OPGN)’s senior vice president of research and development.

Last week’s rally did little to reverse a strong downtrend that has engulfed OpGen Shares. The stock is currently trading at the lower end of a tight $0.30-$0.33 trading range closing in on 52-week lows of $0.21 a share. The stock faces immediate resistance at the $0.38 mark, above which it could rise to highs of $0.40 a share.

Q2 Earnings Report

Separately, OpGen Inc (NASDAQ:OPGN) reported a net loss of (-$4.2) million for the three months ended June 30, 2017, compared to a net loss of (-$5.1) million reported last year. The company has embarked on a cost saving drive that seeks to trim operating expenses by 25% – 30%.

Revenue in the quarter fell to $0.7 million from $1.2 million in Q2 2016. Revenue for the first six months of the year came in at $1.5 million compared to $2.3 million for the six months ended June 30, 2016.

During the second quarter, OpGen Inc (NASDAQ:OPGN) completed a $10 million public offering of its common stock in which it generated $8.7 million in net proceeds. The funds are to be used to accelerate the development of the Acuitas Rapid Test and our Acuitas Lighthouse Knowledgebase. The company also entered into a global supply agreement with Thermo Fisher Scientific for the use of their technology to support the commercialization of rapid molecular products and informatics systems.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

OpGen Inc (NASDAQ:OPGN) Stock Follows Trend

OpGen Inc (NASDAQ:OPGN)

OpGen Inc (NASDAQ:OPGN) stock was down $0.02 at the close of today’s trading as investors absorbed its Q2 financial report after yesterday’s market close. OpGen Inc (NASDAQ:OPGN) reported a Q2 (-$4.2) million net loss compared with $5.1 million for Q2 2016. Net loss for the six months ended June 30, 2017 was $9.2 million compared with $9.6 million for the six months ended June 30, 2016.

OpGen Inc (NASDAQ:OPGN)
One month OPGN Stock Price Chart

OpGen’s total Q2 revenue was $0.7 million compared with $1.2 million for Q2 2016. Total revenue for the six months ended June 30, 2017 was $1.5 million compared with $2.3 million for the six months ended June 30, 2016.

OpGen Inc (NASDAQ:OPGN) Q2 operating expenses were $4.9 million compared with $6.2 million for the same period in 2016. Operating expenses for the six months ended June 30, 2017 were $10.6 million compared with $11.8 million for the six months ended June 30, 2016.

Cash and cash equivalents were $0.2 million as of June 30, 2017 compared with $4.1 million as of December 31, 2016. Subsequent to the close of Q2, OpGen Inc (NASDAQ:OPGN)  raised net proceeds of $8.7 million in a public offering.

OpGen stock is sitting on its 52-week lows of $0.30. OpGen shares have lost over 72% YTD, and are down over 85% for the year. Dilution has been an issue for shareholders. In 2014 10.72 million shares were outstanding but by 2016 that number ballooned to 17.67 million. Sales did improve from 2015 when OpGen posted a sales figure of $3.2 million which was followed in 2016 by a figure of $4.0 million. Meanwhile, per share losses have been the norm. For 2016 each share lost (-$1.10).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN stock and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

OpGen Inc (NASDAQ:OPGN)

Why Beleaguered OpGen Inc (NASDAQ:OPGN) Gained 18%+

OpGen Inc (NASDAQ:OPGN)

Shares of OpGen Inc (NASDAQ:OPGN) were up by 18.75% after the company announced the closing of a $10 million public offering. The company intends to use the net proceeds from the offering to develop its rapid antibiotic resistance diagnostic product and to repay outstanding bridge financing notes.

OpGen Inc (NASDAQ:OPGN)
$OPGN one-year Daily Candle Bar Graph

The offering saw OpGen Inc (NASDAQ:OPGN) issue a total of 18,164,194 units at $0.40 a unit and 6,835,805 units at $0.39 a unit. Each unit issued consists of one share of common stock and one warrant for the purchase of one share of common stock at an exercise price of $0.425 a share. H.C Wainwright & Co LLC acted as the exclusive placement agent for the offering.

“We are pleased this public offering involving new and existing shareholders, as well as members of management, has been completed and look forward to advancing our business strategy,” said Evan Jones, Chief executive officer.

OpGen Inc (NASDAQ:OPGN) is a precision medicine company that leverages the power of informatics and genomic analysis to develop solutions for combatting infectious diseases. The company is also working on providing precise diagnostic information with the help of pathogen surveillance data. It’s deoxyribonucleic acid DNA tests and bioinformatics are designed to address the threat of resistance to antibiotics.

Thermo Fisher Agreement

The company has inked a global supply agreement with Thermos Fisher Scientific technology for the support and commercialization of its rapid molecular products and informatics system. The system is designed to combat multi drug resistant infections. The New York State Department of Health has already approved the use of Acuitas MDRO Gene Test for use by physicians and healthcare providers in the state.

Under the terms of the agreement, OpGen Inc (NASDAQ:OPGN) is to combine its genomic analysis and bioinformatics technology with its peer’s real-time PCR solutions. The integration seeks to make it easier for healthcare providers to rapidly and accurately identify bacterial antibiotic susceptibility.

OpGen Inc (NASDAQ:OPGN) has also been given the go ahead to commercialize its Acuitas Rapid Test for Pathogen id in Thermo Fisher’s PCR system.

“This effort supports our commitment to advancing the latest in molecular testing to help hospitals and health systems rapidly and accurately streamline protocols for informed decision-making in acute care settings,” said Mr. Jones.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

OpGen Inc (NASDAQ:OPGN) Acuitas MDRO Gene Test Approved In New York

OpGen Inc (NASDAQ:OPGN)

OpGen Inc (NASDAQ:OPGN) stock traded lower after announcing the approval of its Acuitas MDRO Gene Test by the New York State Department of Health for use by healthcare providers. The stock was down by 6.46% to end Wednesday’s trading session at $0.419 a share. Today, the stock gapped down on the open but has regained some of the lost value.

OpGen NASDAQ:OPGN
15 minute candle bar graph for NASDAQ:OPGN

New York Milestone

It awaits to be seen if the pull back is a minor correction on an upside run given that OpGen Inc (NASDAQ:OPGN) is currently trading in a tight $0.38-$0.419 trading range. The stock continues to trade on a downward trend with immediate resistance at the $1 a share mark.

OpGen Inc (NASDAQ:OPGN) bills itself as a precision medicine company that uses molecular diagnostic and informatics to combat infectious diseases. The company harnesses the power of informatics and genomic analysis to develop solutions for patient and network-wide infection prevention and treatment.

Approval of MDRO Gene Test in New York is a milestone achievement that validates the company’s technology in the detection of multi-drug resistant organisms. The Acuitas MDRO is designed to provide information about the presence of up to ten MDRO resistance gene on patients specimens.

Multi-Drug resistant organisms are a leading cause of healthcare-acquired infections and a major cause of high morbidity and mortality. More than two million Americans acquire such infections every year. Test results from MDRO Gene Test are normally used to identify patients with drug-resistant genes.

“We are pleased to receive approval by the NYSDOH to provide our services to healthcare institutions in NY State. […]By making our testing available to NY State healthcare providers, we hope to help combat the rising Superbug Multi-drug Resistant pathogen issue,” said CEO, Evan Jones.

Thermo Fisher Agreement

OpGen Inc (NASDAQ:OPGN) recently entered into a global supply agreement for the use of Thermo Fisher Scientific’s technology to advance the Acuitas Rapid Test. The company is to combine Thermo Fisher PCR solutions and its bioinformatics technology to help healthcare providers identify antibiotic susceptibility using resistance gene profiles.

Under the terms of the agreement, OpGen Inc (NASDAQ:OPGN) is to commercialize its molecular products and informatics system on Thermo Fisher real-time PCR system. According to the Chief Executive Officer, the partnership should help health systems make better informed decisions in acute care settings.

“Thermo Fisher’s market leading position in PCR, its global install base makes them an ideal partner for our Acuitas Rapid Test,” said Mr. Jones.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OpGen Inc. (NASDAQ:OPGN) Focused On Acuitas Family Products Development After Q1 Net loss

OpGen Inc. (NASDAQ:OPGN)

OpGen Inc. (NASDAQ:OPGN) is in the process of transitioning its business as focus shifts to developing the Acuitas family of genomic and informatics products. The shift comes on the company posting a wider than expected net loss in Q1 2017, attributed to a decrease in sales of FISH pathogen identification products. The company was also on the receiving end on the discontinuation of genome mapping products.

OpGen Q1 Results

Revenue in the quarter came in at $4.08 million – down from $1.1 million as of Q1 2016. Operating Expenses, on the other hand, soared to highs of $5.7 million from $5.6 million as OpGen Inc. (NASDAQ:OPGN) invested big on the Acuitas Rapid Test development. Net loss soared to highs of $5 million from $4.5 million as of Q1 2016.

Cash and cash equivalent as of the end of the quarter stood at $1.7 million compared to $4.1 million as of December 31, 2016. Development of the Acuitas Rapid Test is a key priority as the company believes it will provide the foundation for growth going forward.

During the quarter the company presented preliminary test results for the technology it hopes to use for the detection of resistance genes in multi-drug resistant pathogens

“In the preliminary results presented at ECCMID, our Acuitas technology demonstrated the ability to rapidly and accurately predict antibiotic susceptibility using resistance gene profiles. The development of our first Acuitas Rapid Test to detect resistance genes for interpretation by our Acuitas Lighthouse informatics is underway,” said CEO, Evan Jones.

2017 Outlook

Focus now shifts to implementing the Acuitas Rapid Test technology for external research use. OpGen is planning to expand the technology knowledge base by essentially completing 4,000 clinical isolates from various clinical sites include Merck SMART surveillance.

OpGen Inc. (NASDAQ:OPGN) is exploring a number of distribution and partnership relationships to support commercialization of the Acuitas Rapid Test. Accelerating growth of the business both in the U.S and on the international scene is also high on the agenda as OpGen looks to unlock new opportunities for growth.

Separately, OpGen Inc. (NASDAQ:OPGN) has confirmed the appointment of Dr. Tina S. Nova to its board of directors. Dr. Nova joins the board with vast experience in building novel genomics-based businesses. She is currently the CEO of Molecular Stethoscope Inc.

OpGen Inc. (NASDAQ:OPGN)’s stock was a big mover in Wednesday trading session having rallied by 6.09% to close at highs of $0.845 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.

OpGen Inc (NASDAQ:OPGN) FY2016 Revenue Jumps 27% YoY

OpGen Inc (NASDAQ:OPGN)

OpGen Inc (NASDAQ:OPGN) posted their financial and operational report for Q4 and year closed December 2016 and summarized business highlights. Total revenue for FY2016 came at $4 million, a 27% jump from $3.2 million posted for the full year closed December 2015. Net loss for the reported year came at $19.2 million versus $17.4 million in 2015.

The update

Evan Jones, the Chairman and CEO of OpGen Inc (NASDAQ:OPGN), reported that in 2016 the investments in informatics and genomics for infectious disease management concerns triggered by multi-drug resistant organisms started to pay off. They successfully moved their Acuitas Rapid Test for drug resistant pathogens and genes and Acuitas Lighthouse antibiotic resistance calculation technology to the advancement phase.

Later in 2017, they expect that the first clinical assessments of this technology along with the launch of RUO test kits. They also recorded major milestones including a strategic research agreement with Merck.

OpGen Inc (NASDAQ:OPGN) reported that total revenue for Q4 2016 stood at $1 million, a decline of 24% from $1.3 million recorded in Q4 2015. However, it recorded a gain of 32% from the third quarter of 2016. For FY2016, the operating expenses came in at $23 million versus $18.2 million in FY2015. Operating expenses for Q4 2016 stood at $5.7 million against $6.2 million in Q4 2015.

Net loss for FY2016 was $19.2 million against $17.4 million in FY2015. While it amounted to $4.8 million in Q4 2016 as against $4.7 million in Q4 2015. Cash and cash equivalents stood at $4.1 million as of close of December 2016 against $4.3 million as of close of September 2016.

The CEO Jones stated that during 2017 they are focused on moving the development of the Acuitas product line together with the Acuitas Lighthouse Knowledgebase with an objective of implementing the know-how for external research application in the second half of the year. They are also working to support the growth of their business in the United States and global markets. The company expect sharing additional technical, health and commercial data that support their capabilities and position as they become available.

OpGen Inc (NASDAQ:OPGN) shares experienced strength last week, continuing their recent uptrend. Their shares price has gained almost 4% over the past week. Over the past one year, the stock has declined almost 30% and declined over 3% in the last quarter.

3/24/2017
Ticker Symbol OPGN
Last Price a/o 3:21 PM EST  $1.07
Average Volume 578.78K
Market Cap (mlns) $24.30M
Shares Outstanding (mlns) 22.71M
Share Float (mlns) 16.15M
Inside Ownership 0.30%
Short Float 9.44%
Short Interest Ratio 2.63
Quarterly Return -3.60%
YTD Return -6.96%
Year Return -30.07%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.